Multiple-marker risk parameters predictive of conversion to diabetes
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova
Life of this patent
Estimating the term…
Loading patent…
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova
Estimating the term…
Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes using defined mathematical models of short term risk (STR) and longer term risk of progression. The evaluations can stratify risk for patients having the same glucose measurement, particularly those with intermediate or low (normal) fasting plasma glucose (FPG) values. The STR or IR (insulin resistance) model(s) may include an inflammatory biomarker such as an NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. Embodiments of the invention also provide methods, systems and circuits that generate STR scores as a marker of beta-cell dysfunction or impairment.
A method of evaluating a subject's risk of developing type 2 diabetes and/or having pancreatic beta cell impairment and/or dysfunction, comprising:
A method of identifying at-risk patients that may benefit from therapies for improving or stabilizing beta-cell function and/or improve a patient's ability to produce insulin, comprising:
A method of identifying subjects that are likely to benefit from a drug therapy for improving pancreatic beta cell function and/or to inhibit Type 2 diabetes mellitus (T2DM), comprising:
Dependencies are inferred from the claim text.